Ineffective Bipolar Disorder Medications 11/06/2010 Global ++Global Industry Analysts' Bipolar Market Report
||Bipolar Disorder Medications
||++Global Industry Analysts’ Bipolar Market Report [Light red] ++ Indicates an important journal article.
Paragraph one reads: June 11, 2010 -- Bipolar disorder is a chronic and devastating psychiatric disease. Since neither curable nor effectively treatable, the bipolar disorder market is present with significant unmet medical needs. The major drawbacks of existing products include dyskinesis, obsessive-compulsive behavior and psychiatric side effects, as well as ineffectiveness in treating cognitive deficits, rapid recycling or depressive symptoms. In addition, though anti-convulsants (such as Valproic acid) and lithium have considerably enhanced disease prognosis, several patients show poor tolerance to treatment-related side effects. Other major clinical setbacks include lack of compliance to treatment regimen, inadequate clinical response, and relapse.
[ SSRI Stories note: Since the Global Industry Analysts paint such an accurate portrait of the failure of medications for bipolar disorder, perhaps it would be better to leave this bipolar condition "latent" or "dormant" [e.g. no antidepressants or ADHD meds] as these doctors suggest in the case of a woman who killed her 11 year old daughter. See: http://ssristories.drugawareness.org/show.php?item=1153
Paragraph 14 reads: "Higgins said Pinckard's doctors believe the Prozac she was taking before the shooting caused her behavior; it acted as a catalyst for a hidden bipolar condition". Last paragraph reads: "Higgins said Pinckard's psychiatrists testified that if she had not taken Prozac, her condition may never have manifested itself. ]
Global Bipolar Disorders Market to Reach $5.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc.GIA announces the release of a comprehensive global report on Bipolar Disorder markets. The world market for bipolar disorder is projected to reach $5.7 billion by the year 2015. Patent expiries of some of the major drugs, and a weak drug pipeline are expected to hamper growth of the bipolar disorder market. The loss of marketing exclusivity of two major drugs, Lamictal (lamotrigine) and Risperdal (risperidone) has opened the market for generic competition.
San Jose, California (Vocus/ PRWEB ) June 11, 2010 -- Bipolar disorder is a chronic and devastating psychiatric disease. Since neither curable nor effectively treatable, the bipolar disorder market is present with significant unmet medical needs. The major drawbacks of existing products include dyskinesis, obsessive-compulsive behavior and psychiatric side effects, as well as ineffectiveness in treating cognitive deficits, rapid recycling or depressive symptoms. In addition, though anti-convulsants (such as Valproic acid) and lithium have considerably enhanced disease prognosis, several patients show poor tolerance to treatment-related side effects. Other major clinical setbacks include lack of compliance to treatment regimen, inadequate clinical response, and relapse.
The United States dominates the world bipolar disorder market as stated by the new market research report on bipolar disorder market. According to the U.S. National Institute of Mental Health, there are about 5.7 million adults aged 18 years and over, suffering from bipolar disorder in the US. The treatment of bipolar disorder differs based on physician specialty in the country. Most psychiatrists follow the recommendations of the American Psychological Association and prescribe lithium, valproic acid and atypical antipsychotics as first-line monotherapies for bipolar mania, and Lamictal as the recommended treatment for bipolar depression. And, unlike the psychiatrists who follow the APA guidelines and prescribe Lamictal first-line, primary care physicians select antidepressants first line.
Bipolar Disorders: A Global Strategic Business Report
Bipolar disorder is highly consolidated marketplace with the leading five players accounting for the lion’s share of the market. These players are unlikely to face any major challenge(s) in the future, as pipeline molecules are all targeted at providing only symptomatic relief, and no company is developing any therapy that promises a paradigm shift in the treatment of bipolar disorder. Key players profiled in the report include Abbott Laboratories Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company, Forest Laboratories Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica Inc., Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Repligen Corporation, and Validus Pharmaceuticals Inc.
The report titled “Bipolar Disorders: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a review of unmet medical needs, opportunities and challenges, patent expiries, competitive scenario, select leading products, select pipeline drugs, clinical trials, product approvals/launches, recent industry activity, and coverage on major global market participants. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe, Asia-Pacific and Rest of World. Global market is analyzed by the following drug classes - Atypical Anti-psychotics and Other Therapeutics.
For more details about this market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/